Engineered Mycobacterium smegmatis-based intrapleural immunotherapy remodels the pleural immune microenvironment for malignant pleural effusion treatment
6 affiliations
- 1Department of Oncology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University
- 2Department of Radiation Oncology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University
- 3Department of Pathology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University
- 4Department of Thoracic Surgery, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University
- 5Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, School of Life Sciences, Nanjing University
- 6Department of Respiration, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University
Abstract
Background: Malignant pleural effusion (MPE) is a common and devastating complication of advanced malignancies, particularly lung cancer, with limited therapeutic options and poor prognosis. Immune checkpoint inhibitors and cytokine therapies have shown promise in solid tumors but are constrained by dose-dependent toxicity and limited efficacy in the pleural cavity. Engineered Mycobacterium smegmatis ( M. smegmatis ) co-expressing a PD-L1 inhibitor and interleukin-15 immunocytokine (Ms-PI15) represents a novel in situ vaccine platform capable of sustained local drug delivery with favorable biosafety profiles. Here, we investigated the therapeutic efficacy and underlying mechanisms of intrapleural Ms-PI15 administration in a murine MPE model.
Methods: A syngeneic MPE mouse model was established by intrapleural inoculation of luciferase-expressing Lewis lung carcinoma (LLC-Luc) cells into C57BL/6 mice. Mice were treated with intrapleural injections of PBS, Ms-vector (empty vector control), or Ms-PI15. Tumor burden was monitored by bioluminescence imaging. Pharmacokinetics and biodistribution of Ms-PI15 were evaluated using DIR fluorescence imaging and bacterial colony enumeration. Flow cytometry and immunohistochemistry were employed to characterize immune cell populations in the tumor microenvironment, spleen, and thoracic draining lymph nodes (TDLNs). Biosafety was assessed by histopathological examination and serum biochemistry.
Results: Intrapleural administration of Ms-PI15 significantly suppressed MPE development and pleural tumor growth compared with PBS and Ms-vector controls. DIR fluorescence imaging and CFU enumeration demonstrated that Ms-PI15 accumulated predominantly in the pleural tumor microenvironment and TDLNs, peaking at 72 h post-administration, with minimal dissemination to distant organs. Mechanistically, Ms-PI15 remodeled the immune microenvironment by promoting maturation of CD80 ⁺ CD86 ⁺ myeloid dendritic cells (mDCs), driving M1 polarization of tumor-associated macrophages (increased CD86 ⁺ , decreased CD206 ⁺ ), and significantly enhancing infiltration of CD8 T cells and NK1.1 ⁺ NK cells in the pleural tumor, spleen, and TDLNs. No significant histopathological abnormalities or serum biochemical alterations were observed in major organs following Ms-PI15 treatment, confirming its favorable biosafety profile.
Conclusion: Intrapleural administration of the engineered M. smegmatis Ms-PI15 effectively inhibits MPE progression by remodeling the pleural immune microenvironment toward an antitumor phenotype, while maintaining excellent biosafety. These findings provide a preclinical foundation for the development of intracavitary bacterial immunotherapy as a novel treatment strategy for malignant pleural effusion.
Related
- Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy
- Loss of function of LprG-Rv1410c and MmpL11 homologues in Mycobacterium smegmatis leads to altered glycopeptidolipid profile and decreased cellular c-di-GMP levels during biofilm formation
- Identification of novel inhibitors of Mycobacterium smegmatis growth through genome-wide overexpression of Cluster P3 mycobacteriophage Xavia genes
- Enhancing Mycobacterial Clearance via Heterologous BCG Prime Boost Strategy Using Recombinant Mycobacterium smegmatis
- Genome-wide CRISPRi mapping of mycobacteriophage interaction determinants in Mycobacterium smegmatis mc2155
BibTeX
@article{zhou2026engineered,
title = {{Engineered Mycobacterium smegmatis-based intrapleural immunotherapy remodels the pleural immune microenvironment for malignant pleural effusion treatment}},
author = {Leilei Zhou and Zhaoye Qian and Rong Yao and Cheng Chen and Peng Pan and Zhongying Guo and Zhongneng Xu and Yi Mei and Jipeng Wang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1972278},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1972278/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Engineered Mycobacterium smegmatis-based intrapleural immunotherapy remodels the pleural immune microenvironment for malignant pleural effusion treatment
AU - Leilei Zhou
AU - Zhaoye Qian
AU - Rong Yao
AU - Cheng Chen
AU - Peng Pan
AU - Zhongying Guo
AU - Zhongneng Xu
AU - Yi Mei
AU - Jipeng Wang
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1972278
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1972278/full
AB - Background: Malignant pleural effusion (MPE) is a common and devastating complication of advanced malignancies, particularly lung cancer, with limited therapeutic options and poor prognosis. Immune checkpoint inhibitors and cytokine therapies have shown promise in solid tumors but are constrained by dose-dependent toxicity and limited efficacy in the pleural cavity. Engineered Mycobacterium smegmatis ( M. smegmatis ) co-expressing a PD-L1 inhibitor and interleukin-15 immunocytokine (Ms-PI15) represents a novel in situ vaccine platform capable of sustained local drug delivery with favorable biosafety profiles. Here, we investigated the therapeutic efficacy and underlying mechanisms of intrapleural Ms-PI15 administration in a murine MPE model. Methods: A syngeneic MPE mouse model was established by intrapleural inoculation of luciferase-expressing Lewis lung carcinoma (LLC-Luc) cells into C57BL/6 mice. Mice were treated with intrapleural injections of PBS, Ms-vector (empty vector control), or Ms-PI15. Tumor burden was monitored by bioluminescence imaging. Pharmacokinetics and biodistribution of Ms-PI15 were evaluated using DIR fluorescence imaging and bacterial colony enumeration. Flow cytometry and immunohistochemistry were employed to characterize immune cell populations in the tumor microenvironment, spleen, and thoracic draining lymph nodes (TDLNs). Biosafety was assessed by histopathological examination and serum biochemistry. Results: Intrapleural administration of Ms-PI15 significantly suppressed MPE development and pleural tumor growth compared with PBS and Ms-vector controls. DIR fluorescence imaging and CFU enumeration demonstrated that Ms-PI15 accumulated predominantly in the pleural tumor microenvironment and TDLNs, peaking at 72 h post-administration, with minimal dissemination to distant organs. Mechanistically, Ms-PI15 remodeled the immune microenvironment by promoting maturation of CD80 ⁺ CD86 ⁺ myeloid dendritic cells (mDCs), driving M1 polarization of tumor-associated macrophages (increased CD86 ⁺ , decreased CD206 ⁺ ), and significantly enhancing infiltration of CD8 T cells and NK1.1 ⁺ NK cells in the pleural tumor, spleen, and TDLNs. No significant histopathological abnormalities or serum biochemical alterations were observed in major organs following Ms-PI15 treatment, confirming its favorable biosafety profile. Conclusion: Intrapleural administration of the engineered M. smegmatis Ms-PI15 effectively inhibits MPE progression by remodeling the pleural immune microenvironment toward an antitumor phenotype, while maintaining excellent biosafety. These findings provide a preclinical foundation for the development of intracavitary bacterial immunotherapy as a novel treatment strategy for malignant pleural effusion.
SN - 1663-9812
ER -